JP2019535822A5 - - Google Patents

Download PDF

Info

Publication number
JP2019535822A5
JP2019535822A5 JP2019547064A JP2019547064A JP2019535822A5 JP 2019535822 A5 JP2019535822 A5 JP 2019535822A5 JP 2019547064 A JP2019547064 A JP 2019547064A JP 2019547064 A JP2019547064 A JP 2019547064A JP 2019535822 A5 JP2019535822 A5 JP 2019535822A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
liver
reducing
fat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019547064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535822A (ja
Filing date
Publication date
Priority claimed from MX2016014775A external-priority patent/MX364040B/es
Application filed filed Critical
Publication of JP2019535822A publication Critical patent/JP2019535822A/ja
Publication of JP2019535822A5 publication Critical patent/JP2019535822A5/ja
Priority to JP2022152261A priority Critical patent/JP2022173344A/ja
Pending legal-status Critical Current

Links

JP2019547064A 2016-11-11 2017-11-09 ヒト脂肪性肝炎(nafld/nash)の治療及び回復に対するピルフェニドンを含む持続放出性の組成物の薬学的使用 Pending JP2019535822A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022152261A JP2022173344A (ja) 2016-11-11 2022-09-26 ヒト脂肪性肝炎(nafld/nash)の治療及び回復に対するピルフェニドンを含む持続放出性の組成物の薬学的使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MXMX/A/2016/014775 2016-11-11
MX2016014775A MX364040B (es) 2016-11-11 2016-11-11 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
PCT/MX2017/000129 WO2018088886A1 (es) 2016-11-11 2017-11-09 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022152261A Division JP2022173344A (ja) 2016-11-11 2022-09-26 ヒト脂肪性肝炎(nafld/nash)の治療及び回復に対するピルフェニドンを含む持続放出性の組成物の薬学的使用

Publications (2)

Publication Number Publication Date
JP2019535822A JP2019535822A (ja) 2019-12-12
JP2019535822A5 true JP2019535822A5 (enExample) 2020-12-17

Family

ID=61193005

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019547064A Pending JP2019535822A (ja) 2016-11-11 2017-11-09 ヒト脂肪性肝炎(nafld/nash)の治療及び回復に対するピルフェニドンを含む持続放出性の組成物の薬学的使用
JP2022152261A Pending JP2022173344A (ja) 2016-11-11 2022-09-26 ヒト脂肪性肝炎(nafld/nash)の治療及び回復に対するピルフェニドンを含む持続放出性の組成物の薬学的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022152261A Pending JP2022173344A (ja) 2016-11-11 2022-09-26 ヒト脂肪性肝炎(nafld/nash)の治療及び回復に対するピルフェニドンを含む持続放出性の組成物の薬学的使用

Country Status (21)

Country Link
US (3) US20190262325A1 (enExample)
EP (1) EP3539537A1 (enExample)
JP (2) JP2019535822A (enExample)
KR (2) KR20190084056A (enExample)
CN (2) CN110248646A (enExample)
AR (1) AR110057A1 (enExample)
AU (2) AU2017358367B2 (enExample)
CA (1) CA3043300A1 (enExample)
CL (1) CL2019001280A1 (enExample)
CO (1) CO2019004799A2 (enExample)
EC (1) ECSP19031851A (enExample)
IL (1) IL266519A (enExample)
JO (1) JOP20190102A1 (enExample)
MA (1) MA45754A1 (enExample)
MX (1) MX364040B (enExample)
PE (1) PE20191149A1 (enExample)
PH (1) PH12019501047A1 (enExample)
RU (1) RU2019116422A (enExample)
UY (1) UY37478A (enExample)
WO (1) WO2018088886A1 (enExample)
ZA (1) ZA201903012B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
EP3716975A4 (en) * 2017-11-28 2022-01-12 Eiger Biopharmaceuticals, Inc. METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
WO2020115774A1 (en) 2018-12-06 2020-06-11 Cipla Limited High drug load extended release formulations
EP4232063A4 (en) * 2020-10-23 2025-01-01 HAN, Hq BIFUNCTIONAL ANTAGONISTS OF TUMOR NECROSIS FACTOR-ALPHA AND TRANSFORMING GROWTH FACTOR-BETA AND THEIR USES
CN117007806A (zh) * 2023-09-21 2023-11-07 中国人民解放军军事科学院军事医学研究院 靶向肝巨噬细胞内lxr用于控制慢乙肝进展

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
CN100542532C (zh) * 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途
WO2010048716A1 (en) * 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CN102488660A (zh) * 2011-12-15 2012-06-13 西安天一秦昆制药有限责任公司 一种含吡非尼酮的缓释微丸
CN103550242B (zh) * 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法

Similar Documents

Publication Publication Date Title
JP2019535822A5 (enExample)
JP2017178948A5 (enExample)
JP2018184443A5 (enExample)
WO2017141104A3 (en) Method for inducing a sustained immune response
HRP20230170T1 (hr) Derivati kolana za uporabu u liječenju i/ili prevenciji bolesti povezanih s fxr i tgr5/gpbar1
JP2018504445A5 (enExample)
RU2018114447A (ru) Введение дейтерированных усилителей cftr
WO2017087608A8 (en) Modulators of ror-gamma
MX2017001372A (es) Sales de berberina, sales ursodesoxicolicas y combinaciones, metodos de preparacion y aplicacion de las mismas.
WO2005087238A3 (en) Method for stimulating the immune, inflammatory or neuroprotective response
NZ741082A (en) C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
HK1232147A1 (zh) 用於治疗纤维化的赛尼克韦罗
RU2019116422A (ru) Фармацевтическое применение композиции пролонгированного действия, содержащей пирфенидон, для лечения и обращения течения стеатогепатита человека (nafld/nash)
RU2016145066A (ru) Композиция для предотвращения или лечения жировых болезней печени
JP2015535270A5 (enExample)
EP3833373A4 (en) TRIPEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISEASES
JP2017512194A5 (enExample)
RU2019110980A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
MX2020011474A (es) Nuevo tratamiento de enfermedades pulmonares intersticiales.
CN110546150A (zh) 含吡唑基的三并环类衍生物、其制备方法和应用
WO2016040462A3 (en) Formulations and methods for treatment of metabolic syndrome
EP4221704A4 (en) PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF KDM1A-MEDIATED DISEASES
JP2017061488A5 (enExample)
ZA201905309B (en) Pharmaceutical active ingredient and use thereof, in particular for the prevention and treatment of metabolic disorders in humans and animals